Company Overview and News

1
S P Setia, MNC Wireless, M3Tech, CCK Consolidated, NetX, Zhulian, GHL, Alcom, Heineken, Lion Industries, Berjaya Assets, PDZ, MAA Group and AsiaBio

2017-04-12 theedgemarkets
KUALA LUMPUR (April 12): Based on corporate announcements and news flow today, companies in focus on Thursday (April 13) may include the following: S P Setia, MNC Wireless, M3Tech, CCK Consolidated, NetX, Zhulian, GHL, Alcom, Heineken, Lion Industries, Berjaya Assets, PDZ, MAA Group and AsiaBio.

 
KLCI remains in the red as selling persists

2017-02-16 theedgemarkets
KUALA LUMPUR (Feb 16): The FBM KLCI remained in negative territory at the midday break today as traders sold into strength and decliners led advancers.

 
Hexza, Sinotop, Appasia, Focus Dynamics, Asia Bioenergy

2016-11-04 theedgemarkets
KUALA LUMPUR (Nov 4): theedgemarkets.com highlighted five stocks with momentum at Bursa Malaysia's afternoon market close today. All five stocks displayed negative momentum.

 
KLCI down 6.04pts at midday as Asian markets continue decline

2016-10-27 theedgemarkets
KUALA LUMPUR (Oct 27): The FBM KLCI was down 6.04 points or 0.36% to 1,667.88 at the midday close as major Asian markets fell for a second day as the US election nears and investors remained concerned that the US Federal Reserve will raise interest rates this year.

 
Teck Guan, Asia Bioenergy, AT Systematization, ConnectCounty, Guan Chong, Hiap Teck, KPS Consortium, Apex Healthcare and TPC

2016-09-30 theedgemarkets
KUALA LUMPUR (Sept 30): theedgemarkets.com highlighted nine stocks with momentum at Bursa Malaysia's afternoon market close today. Four stocks showed positive momentum, while five had negative momentum.   Stocks with positive momentum were:

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...